Lobbying client
EXELA PHARMA SCIENCES
Injectable and ophthalmic pharmaceutical products.
The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 3 of its records are shown together here.
Filings
58
Filed by
3
Reported in-house
—
Reported by firms
$2,287,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2017 to 2026
Filings
1 filing for 2017, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
4th Quarter - Report (No Activity) 4th Quarter 2017
|
BROYDRICK & ASSOCIATES | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| OLD NORTH STRATEGIES, LLC | 19 | $1,707,000 |
| FIDELIS GOVERNMENT RELATIONS | 7 | $390,000 |
| BROYDRICK & ASSOCIATES | 28 | $190,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 27 |
| Pharmacy | PHA | 20 |
| Manufacturing | MAN | 19 |
| Medical/Disease Research/Clinical Labs | MED | 18 |
| Science/Technology | SCI | 1 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.